Recursion Pharma: H2 2024 Data Readouts Are Major Inflection Points (NASDAQ:RXRX) -LSB

11 Min Read

Bacterial cell. Microscope view. Scientific medical illustration.

JuSun/iStock via Getty Images

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has made great progress recently in being able to advance its pipeline. That’s because it has advanced two clinical candidates into phase 2 studies. It uses its recursion system to

Share This Article
Leave a comment
HTML Snippets Powered By :
error: Content is protected !!